High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.
about
Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitationHigh-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivoOptimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft modelEnhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variantsCapsid Mutated Adeno-Associated Virus Delivered to the Anterior Chamber Results in Efficient Transduction of Trabecular Meshwork in Mouse and RatSingle point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivoReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerSite-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In VivoPerspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene TherapyEfficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors.Microglia-specific targeting by novel capsid-modified AAV6 vectors.Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.Particle platforms for cancer immunotherapy.Advances in AAV vector development for gene therapy in the retina.Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy.E2F-1 promotes DAPK2-induced anti-tumor immunity of gastric cancer cells by targeting miR-34a.Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced DosesProteomics analysis of co-purifying cellular proteins associated with rAAV vectors.Generation of Helper Plasmids Encoding Mutant Adeno-associated Virus Type 2 Capsid Proteins with Increased Resistance against Proteasomal Degradation.A novel and high efficient AAV6 mutant.
P2860
Q33586309-695E637E-595C-4BD8-BCFE-D9AD4CCAEC63Q34629995-DBA0A976-52A1-4FA7-9670-21CEDD5B7BB5Q34634722-80C0845D-0F2B-4C4F-81B9-B0B1EC4BA398Q34700925-EA5DF0A0-BEDD-4039-BE2C-08EB990564AEQ34729878-CF2BC145-DF5B-42F4-B6D6-C0F379F03BE4Q34991117-178A27BD-2B59-4F8E-8001-761E0C875A66Q35210473-06702B1C-C973-4DEE-B236-D939FC5C9350Q35656153-FF239117-BBDD-4860-9473-AE52CA9BC8DDQ35884767-E150273A-2431-4509-9374-FD548B7D42BEQ35949356-20F8D885-7F93-4E1A-9B51-C7912C5FCB9AQ36367714-DB13852D-1472-4C5F-A7F7-B9AFA06DDBF1Q36406869-89F2602D-0D8B-4D7E-990C-4C31F76F1E6CQ36427096-70A9C6DA-BDDF-4AC2-AF90-5B7391D18916Q37007749-CF50F226-313C-4B14-A2E1-E4BB0162C081Q37011792-4A52A7FD-711F-4ACE-BEA2-9E2C2EC9149DQ37066323-09BB874D-0A86-4E52-A058-65F9BC5BC8B7Q38114060-E214541D-6F92-4878-87C1-67997F011C5EQ38199047-169A40BB-6ED5-418B-A93D-6B145566D763Q38843995-5E38E343-1663-4F78-8545-A2D05BA65732Q39064354-4B55CB54-16C5-4A89-B169-E877F5DC160EQ39321877-DC0C3CDA-1205-4FE4-825E-2B50F6636A0EQ40644650-BE701AFC-3822-4D98-8EEE-C46CCCCD92A8Q41778815-96E136E8-78B2-4F2B-ACB9-3C66D3C2D615Q41820481-9EE755F1-9896-4D52-B65E-E5E1EFACB60FQ47215206-C00C8800-2EB8-4151-B05B-FD6C4D3D958C
P2860
High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@ast
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@en
type
label
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@ast
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@en
prefLabel
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@ast
High-efficiency transduction o ...... fied recombinant AAV2 vectors.
@en
P2093
P2860
P50
P1433
P1476
High-efficiency transduction o ...... ified recombinant AAV2 vectors
@en
P2093
Arun Srivastava
Giridhara R Jayandharan
Lakshmanan Govindasamy
Luis Ortiz
Mavis Agbandje-McKenna
Sergei Zolotukhin
P2860
P304
P356
10.1016/J.VACCINE.2012.03.079
P407
P577
2012-04-10T00:00:00Z